Introduction
============

We propose this study in order to reach two points: the clinical incidence of vasospasm morbidity, confirmed by CT; and the mortality of subarachnoid hemorrhage (SAH) patients in 28 days \[[@B1]\]. It shows the comparison of a group of patients that used magnesium (Mg) (intervention, Group 1) with those that did not use Mg (control, Group 2).

Methods
=======

After institutional approval and informed consent, a prospective, randomized, nonblind study was carried out between February and November 2008. The main goal of the study was to achieve a Mg serum concentration from 2.5 to 3.5 mg/dl, using a solution of Mg 2% (saline solution 5% 400 ml + MgSO~4~10% 100 ml/24 hours), during the first 14 days of aneurysm rupture. Admission criteria: patients diagnosed with SAH and Δ*T*\<96 hours. Exclusion criteria: patients with SAH and Δ*T*\>96 hours.

Results
=======

In a previous study evaluation we analysed a total of 56 patients with (n = 26 in Group 1 and n = 30 in Group 2) (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Main results: Group 1 -- vasospasm frequency 26.9% (n = 7) and mortality 19.2% (n = 5) in 28 days; Group 2 -- vasospasm frequency 46.7% (n = 14) and mortality 33.3% (n = 10) in 28 days.

                      Average age   APACHE II score   Average Mg level
  ------------------- ------------- ----------------- ------------------
  Group I (n = 26)    52.3          8.2               2.32
  Group II (n = 30)   50.3          15.6              1.9

                         Group I (n = 26)   Group II (n = 30)                                        
  ---------------------- ------------------ ------------------- ----- ----------- -------------- --- -----
  Vasospasm              26.9 (7)           11.6 to 47.8        0.4   46.7 (14)   28.3 to 65.7   1   0.1
  Mortality in 28 days   19.2 (5)           6.6 to 39.4         0.5   33.3 (10)   17.3 to 52.8   1   0.2

Conclusion
==========

According to the outcome, we can conclude that Group 1 obtained greater protection on the vasospasm incidence and decrease of mortality in comparison with Group 2. The *P*value was not significant due to a still small number of patients.
